Zhang TD, Li YS. Clinical analysis and empirical study on treatment of Ailing No. 1 in 62 cases of acute promyelocytic leukemia. J Integr Tradit West Med (Chin) 1984;1:19.

Chen GQ, Zhu J, Shi XG, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996;88:1052-1061.

Barbey JT. Cardiac toxicity of arsenic trioxide. Blood 2001;98:1632-1634.

Hofmann WK, Koeffler HP. Myelodysplastic syndrome. Annu Rev Med 2005;56:1-16.

Acquaviva C, Gelsi-Boyer V, Birnbaum D. Myelodysplastic syndromes: lost between two states? Leukemia 2010;24:1-5.

List A, Beran M, DiPersio J, et al. Opportunities for Trisenox® (arsenic trioxide) in the treatment of myelodysplastic syndromes. Leukemia 2003;17:1499-1507.

Tuzuner N, Cox C, Rowe JM, et al. Hypocellular myelodysplastic syndromes (MDS): new proposals. Br J Haematol 1995;91:612-617.

Ma R. Treatment of bone marrow failure syndrome with integrated traditional and Western medicine. Chin J Integr Med 2007;13:85-88.

Riggs AD. X inactivation, differentiation, and DNA methylation.Cytogenet Cell Genet 1975;14:9-25.

Holliday R, Pugh JE. DNA modification mechanisms and gene activity during development. Science 1975;187:226-232.

Shen L, Kantarjian H, Guo Y, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010;28:605-613.

Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-428.

Pharmacopoeia of the People's Republic of China. Realgar. Chinese Pharmacopoeia Commission; 2015.

Ballirano P, Maras A. In-situ X-ray transmission powder diffraction study of the kinetics of the light induced alteration of realgar(α-As4S4). Eur J Mineral 2006;18:589-599.

Trentelman K, Stodulski L, Pavlosky M. Characterization of pararealgar and other light-induced transformation products from realgar by Raman microspectroscopy. Anal Chem 1996;68:1755-1761.

Kyono A, Kimata M, Hatta T. Light-induced degradation dynamics in realgar: in situ structural investigation using single-crystal X-ray diffraction study and X-ray photoelectron spectroscopy. Am Mineral 2005;90:1563-1570.

Wu J, Shao Y, Liu J, et al. The medicinal use of realgar (As4S4) and its recent development as an anticancer agent. J Ethnopharmacol 2011;135:595-602.

Lu DP, Qiu JY, Jiang B, et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood 2002;99:3136-3143.

Przygoda G, Feldmann J, Cullen WR. The arsenic eaters of Styria: a different picture of people who were chronically exposed to arsenic.Appl Organomet Chem 2001;15:457-462.

Liu J, Lu Y, Wu Q, Goyer RA, et al. Mineral arsenicals in traditional medicines: orpiment, realgar, and arsenolite. J Pharmacol Exp Ther 2008;326:363-368.

Baláž P, Fabián M, Pastorek M, et al. Mechanochemical preparation and anticancer effect of realgar As4S4 nanoparticles. Mater Lett 2009;63:1542-1544.

Ma PY, Fu ZY, Su YL, et al. The nano pulverization of traditional Chinese medicine Liuwei Dihuang. J Wuhan Univ Technol (Chin)2006;21:105-108.

Rowland IR, Davies MJ. In vitro metabolism of inorganic arsenic by the gastrointestinal microflora of the rat. J Appl Toxicol 1981;1:278-283.

Gong Z, Lu X, Ma M, et al. Arsenic speciation analysis. Talanta 2002;58:77-96.

Gregus Z, Németi B. Purine nucleoside phosphorylase as a cytosolic arsenate reductase. Toxicol Sci 2002;70:13-19.

Yin ZL, Dahlstrom JE, Le Couteur DG, et al. Immunohistochemistry of omega class glutathione S-transferase in human tissues. J Histochem Cytochem 2001;49:983-987.

Wang QQ, Thomas DJ, Naranmandura H. Importance of being thiomethylated: formation, fate, and effects of methylated thioarsenicals. Chem Res Toxicol 2015;28:281-289.

Challenger F. Biological methylation. Chem Rev 1945;36:315-361.

Goering PL, Aposhian HV, Mass MJ, et al. The enigma of arsenic carcinogenesis: role of metabolism. Toxicol Sci 1999;49:5-14.

Suzuki KT, Mandal BK, Ogra Y. Speciation of arsenic in body fluids.Talanta 2002;58:111-119.

Mandal BK, Ogra Y, Suzuki KT. Identification of dimethylarsinous and monomethylarsonous acids in human urine of the arsenic-affected areas in West Bengal, India. Chem Res Toxicol 2001;14:371-378.

Aposhian HV, Gurzau ES, Le XC, et al. Occurrence of monomethylarsonous acid in urine of humans exposed to inorganic arsenic. Chem Res Toxicol 2000;13:693-697.

Styblo M, Del Razo LM, Vega L, et al. Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch Toxicol 2000;74:289-299.

Hayakawa T, Kobayashi Y, Cui X, et al. A new metabolic pathway of arsenite: arsenic–glutathione complexes are substrates for human arsenic methyltransferase Cyt19. Arch Toxicol 2005;79:183-191.

Lu M, Wang H, Li XF, et al. Evidence of hemoglobin binding to arsenic as a basis for the accumulation of arsenic in rat blood.Chem Res Toxicol 2004;17:1733-1742.

Suzuki KT, Katagiri A, Sakuma Y, et al. Distributions and chemical forms of arsenic after intravenous administration of dimethylarsinic and monomethylarsonic acids to rats. Toxicol Appl Pharmacol 2004;198:336-344.

Rehman K, Naranmandura H. Arsenic metabolism and thioarsenicals. Metallomics 2012;4:881-892.

Hughes MF, Kenyon EM, Edwards BC, et al. Accumulation and metabolism of arsenic in mice after repeated oral administration of arsenate. Toxicol Appl Pharmacol 2003;191:202-210.

Wen L, Lou YQ, Jiang B, et al. Pharmacokinetics of tetra-arsenic tetra-sulfide in mice. Chin Pharm J (Chin) 2006;41:619-623.

Zhang YN, Sun GX, Williams PN, et al. Assessment of the solubility and bio-accessibility of arsenic in realgar wine using a simulated gastrointestinal system. Sci Total Environ 2011;409:2357-2360.

Gao XX, Wang XQ, Ma JJ. Treatment of arsenic disulfide in 14 cases with myelodysplastic syndrome. J Clin Intern Med (Chin) 1998;3:125.

Xu S, Ma R, Hu X, et al. Clinical observation of the treatment of myelodysplastic syndrome mainly with Qinghuang Powder. Chin J Integr Med 2011;17:834-839.

Hu X, Liu F, Ma R. Application and assessment of Chinese arsenic drugs in treating malignant hematopathy in China. Chin J Integr Med 2010;16:368-377.

Hu XM, Tanaka S, Onda K, et al. Arsenic disulfide induced apoptosis and concurrently promoted erythroid differentiation in cytokine-dependent myelodysplastic syndrome-progressed leukemia cell line F-36p with complex karyotype including monosomy 7. Chin J Integr Med 2014;20:387-393.

Hu XM, Yuan B, Tanaka S, et al. Arsenic disulfide-triggered apoptosis and erythroid differentiation in myelodysplastic syndrome and acute myeloid leukemia cell lines. Hematology 2014;19:352-360.

Xu M, Ren JY, Guo YC, et al. Effects of arsenic disulfide on apoptosis, histone acetylation, toll like receptor 2 activation, and erythropoiesis in bone marrow mononuclear cells of myelodysplastic syndromes patients in vitro. Leuk Res 2017;62:4-11.

Sun SZ, Ma R, Hu XM, et al. Karyotype and DNA-methylation responses in myelodysplastic syndromes following treatment with traditional Chinese formula containing arsenic. Evid Based Complementary Alterna Med 2012;2012:969476.

Zhao P, Liang JB, Deng ZY, et al. Association of gene mutations with response to arsenic-containing compound Qinghuang Powder,in patients with myelodysplastic syndromes. Chin J Integr Med 2019;25:409-415.

Ramsahoye BH, Biniszkiewicz D, Lyko F, et al. Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a. Proc Natl Acad Sci USA 2000;97:5237-5242.

Jones PA, Taberlay PC. DNA methylation and cancer. Prog Drug Res 2011;67:1-23.

Lu SC. S-adenosylmethionine. Int J Biochem Cell Biol 2000;32:391-395.

Lieber CS, Packer L. S-adenosylmethionine: molecular,biological, and clinical aspects—an introduction. Am J Clin Nutr 2002;76:1148S-1150S.

Song Z, Zhou Z, Uriarte S, et al. S-adenosylhomocysteine sensitizes to TNF-α hepatotoxicity in mice and liver cells: a possible etiological factor in alcoholic liver disease. Hepatology 2004;40:989-997.

Bestor TH. The DNA methyltransferases of mammals. Hum Mol genet 2000;9:2395-2402.

Robertson KD. DNA methylation and chromatin-unraveling the tangled web. Oncogene 2002;21:5361-5379.

Jin B, Li Y, Robertson KD. DNA methylation: superior or subordinate in the epigenetic hierarchy?. Genes Cancer 2011;2:607-617.

Smith ZD, Meissner A. DNA methylation: roles in mammalian development. Nat Rev Genet 2013;14:204-220.

Jones PA, Liang G. Rethinking how DNA methylation patterns are maintained. Nat Rev Genet 2009;10:805-811.

Bronner C, Alhosin M, Hamiche A, et al. Coordinated dialogue between UHRF1 and DNMT1 to ensure faithful inheritance of methylated DNA patterns. Genes 2019;10:65.

Zhang H, Ying H, Wang X. Methyltransferase DNMT3B in leukemia.Leuk Lymph 2020;61:263-273.

Rhee I, Jair KW, Yen RW, et al. CpG methylation is maintained in human cancer cells lacking DNMT1. Nature 2000;404:1003-1007.

Liang G, Chan MF, Tomigahara Y, et al. Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol Cell Biol 2002;22:480-491.

Boxer LD, Renthal W, Greben AW, et al. MeCP2 represses the rate of transcriptional initiation of highly methylated long genes. Mol Cell 2020;77:294-309.

Picard N, Fagiolini M. MeCP2: an epigenetic regulator of critical periods. Curr Opin Neurobiol 2019;59:95-101.

Sasidharan NV, Saleh R,Toor SM, et al. Role of DNA methylation in tumor suppressor gene silencing in colorectal cancer. Clin Epigenetics 2020;12:13.

Kulis M, Esteller M. DNA methylation and cancer. Adv Genet 2010;70:27-56.

Lopez-Serra P, Esteller M. DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. Oncogene 2012;31:1609-1622.

Daskalakis M, Nguyen TT, Nguyen C, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood 2002;100:2957-2964.

Lübbert M. Gene silencing of the p15/INK4B cell-cycle inhibitor by hypermethylation: an early or later epigenetic alteration in myelodysplastic syndromes? Leukemia 2003;17:1762-1764.

Paul TA, Bies J, Small D, et al. Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML. Blood 2010;115:3098-3108.

Baba SM, Azad NA, Shah ZA, et al. p15Ink4b loss of expression by promoter hypermethylation adds to leukemogenesis and confers a poor prognosis in acute promyelocytic leukemia patients. Cancer Res Treat 2017;49:790-797.

Aoki E, Uchida T, Ohashi H, et al. Methylation status of the p15INK4B gene in hematopoietic progenitors and peripheral blood cells in myelodysplastic syndromes. Leukemia 2000;14:586-593.

Tien HF, Tang JL, Tsay W, et al. Methylation of the p15INK4B gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br J Haematol 2001;112:148-154.

Ismail EA, EI-Mogy MI, Mohamed DS, et al. Methylation pattern of calcitonin (CALCA) gene in pediatric acute leukemia. J Pediatr Hematol Oncol 2011;33:534-542.

Marinitch DV, Vorobyev IA, Holmes JA, et al. Hypermethylation of 5'-region of the human calcitonin gene in leukemias: structural features and diagnostic significance. Biochemistry 2004;69:340-349.

Roman J, Castillejo JA, Jimenez A, et al. Hypermethylation of the calcitonin gene in acute lymphoblastic leukaemia is associated with unfavourable clinical outcome. Br J Haematol 2001;113:329-338.

Olk-Batz C, Poetsch AR, Nöllke P, et al. Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome.Blood 2011;117:4871-4880.

Aggerholm A, Holm MS, Guldberg P, et al. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol 2006;76:23-32.

Britschgi C,Jenal M, Rizzi M, et al. HIC1 tumour suppressor gene is suppressed in acute myeloid leukaemia and induced during granulocytic differentiation. Br J Haematol 2008;141:179-187.

Roman-Gomez J, Castillejo J A, Jimenez A, et al. 5' CpG island hypermethylation is associated with transcriptional silencing of the p21CIP1/WAF1/SDI1 gene and confers poor prognosis in acute lymphoblastic leukemia. Blood 2002;99:2291-2296.

Aggerholm A, Holm MS, Guldberg P, et al. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol 2006;76:23-32.

Wu SJ, Yao M, Chou WC, et al. Clinical implications of SOCS1,methylation in myelodysplastic syndrome. Br J Haematol 2006;135:317-323.

Mass MJ, Wang L. Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells: a model for a mechanism of carcinogenesis. Mutat Res 1997;386:263-277.

Shao X, Lu R, Guan X, et al. Effects of arsenic trioxide on Id4 methylation status in bone marrow mononuclear cells and its clinical efficacy for myelodysplastic syndrome. Chin J Hematol (Chin)2014;35:247-250.

Ye XS, Liu T,Cui X, et al. Methylation of P15INK4B gene in patients with myelodysplastic syndromes and demethylating effects of drugs.J Sichuan Univer (MSE, Chin) 2007;38:57-59.

Caudill MA, Wang JC, Melnyk S, et al. Intracellular S-adenosylhomocysteine concentrations predict global DNA hypomethylation in tissues of methyl-deficient cystathionine β-synthase heterozygous mice. J Nutr 2001;131:2811-2818.

Saxena R, Bozack AK, Gamble MV. Nutritional influences on one-carbon metabolism: effects on arsenic methylation and toxicity.Annu Rev Nutr 2018;38:401-429.

Länger F, Dingemann J, Kreipe H, et al. Up-regulation of DNA methyltransferases DNMT1, 3A, and 3B in myelodysplastic syndrome. Leuk Res 2005;29:325-329.

Cui X, Wakai T, Shirai Y, et al. Arsenic trioxide inhibits DNA methyltransferase and restores methylation-silenced genes in human liver cancer cells. Hum Pathol 2006;37:298-311.

Reichard JF, Schnekenburger M, Puga A. Long term low-dose arsenic exposure induces loss of DNA methylation. Biochem Biophys Res Commun 2007;352:188-192.

Park WH, Cho YH, Jung CW, et al. Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis.Biochem Bioph Res Co 2003;300:230-235.

Detich N, Hamm S, Just G, et al. The methyl donor S-adenosylmethionine inhibits active demethylation of DNA a candidate novel mechanism for the pharmacological effects of S-adenosylmethionine. J Biol Chem 2003;278:20812-20820.

Finkelstein JD. Pathways and regulation of homocysteine metabolism in mammals. Semin Thromb Hemost 2000;26:219-225.

Lu SC, Tsukamoto H, Mato JM. Role of abnormal methionine metabolism in alcoholic liver injury. Alcohol 2002;27:155-162.

Vertino PM, Sekowski JA, Coll JM, et al. DNMT1 is a component of a multiprotein DNA replication complex. Cell Cycle 2002;1:416-423.

Chen T, Ueda Y, Dodge JE, et al. Establishment and maintenance of genomic methylation patterns in mouse embryonic stem cells by Dnmt3a and Dnmt3b. Mol Cell Biol 2003;23:5594-5605.

Hermann A, Goyal R, Jeltsch A. The Dnmt1 DNA-(cytosine-C5)-methyltransferase methylates DNA processively with high preference for hemi-methylated target sites. J Biol Chem 2004;279:48350-48359.

Song J, Teplova M, Ishibe-Murakami S, Patel DJ. Structure-based mechanistic insights into DNMT1-mediated maintenance DNA methylation. Science 2012;335:709-712.

Chen Z, Zhang Y. Role of mammalilan DNA methyltransferases in development. Annu Rev Biochem 2019; doi: 10.1146/annurev-biochem-103019-102815http://doi.org/10.1146/annurev-biochem-103019-102815.

Yamazaki T, Hatano Y, Taniguchi R, et al. Editing DNA methylation in mammalian embryos. Int J Mol Sci 2020;21:637.

Chen T, Ueda Y, Xie S, et al. A novel Dnmt3a isoform produced from an alternative promoter localizes to euchromatin and its expression correlates with active de novo methylation. J Biol Chem 2002;277:38746-38754.

Hata K, Okano M, Lei H, et al. Dnmt3L cooperates with the Dnmt3 family of de novo DNA methyltransferases to establish maternal imprints in mice. Development 2002;129:1983-1993.